Core Viewpoint - The company has approved a share repurchase plan to buy back its own shares using bank loans and its own funds, with a total amount between RMB 100 million and RMB 200 million, aimed at implementing an employee stock ownership plan [2] Group 1: Share Repurchase Plan - The company will repurchase shares through centralized bidding, with a maximum price of RMB 4.5 per share and a repurchase period of 12 months from the board's approval date [2] - The total amount allocated for the share repurchase will not be less than RMB 100 million and not exceed RMB 200 million [2] - The company has disclosed its share repurchase progress, having repurchased 20.446517 million shares, accounting for 1.36% of the total share capital, with a total transaction amount of RMB 60.3963 million [3] Group 2: Compliance and Regulations - The company is adhering to the relevant regulations regarding share repurchase, including the disclosure of repurchase progress within the first three trading days of each month [3] - The repurchase activities have been conducted in compliance with the Shenzhen Stock Exchange's self-regulatory guidelines [3] - The company will continue to implement the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by law [3]

Group 1 - The core point of the article is that Ruikang Pharmaceutical announced a share buyback plan, intending to repurchase 20.446517 million shares, which represents 1.36% of the company's total share capital as of July 31, 2025 [1]

Core Viewpoint - Ruikang Pharmaceutical (002589.SZ) announced a share buyback plan, repurchasing 20.446517 million shares, which represents 1.36% of the company's total share capital, with a total transaction amount of 60.3963 million yuan [1] Summary by Categories - **Share Buyback Details** - The company repurchased shares through a dedicated securities account via centralized bidding [1] - The highest transaction price was 3.08 yuan per share, while the lowest was 2.75 yuan per share [1] - The total amount spent on the buyback was 60.3963 million yuan, excluding transaction fees [1] - **Compliance and Regulations** - The share buyback is in accordance with the company's established buyback plan and relevant laws and regulations [1]

证券代码：002589 证券简称：瑞康医药 公告编号：2025-039 瑞康医药集团股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2024 年 11 月 7 日召开第五届董事会第十次会议，审议通过了《关于回购公司股份方 案的议案》，同意公司使用银行专项贷款资金及自有资金以集中竞价交易方式回 购公司部分已发行的人民币普通股（A 股），本次回购股份将用于实施员工持股 计划，回购股份的资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购股份的价格不超过人民币 4.5 元/股（含），具体回购股份的数 量以回购期限届满或回购完毕时实际回购的股份数量为准，实施期限为董事会审 议通过回购股份方案之日起 12 个月内。具体内容详见公司于 2024 年 11 月 11 日 在巨潮资讯网披露《第五届董事会第十次会议决议的公告》（2024-036）及《关 于回购公司股份方案暨取得金融机构股票回购专项贷款承诺函的公告》（公告编 号：2024 ...

Group 1 - The core announcement from Ruikang Pharmaceutical indicates that the company plans to repurchase approximately 20.4465 million shares, which represents 1.36% of its total share capital, with a total transaction amount of 60.3963 million yuan [2] - The share repurchase was conducted through a centralized bidding method, with a maximum transaction price of 3.08 yuan per share and a minimum price of 2.75 yuan per share [2] - For the fiscal year 2024, Ruikang Pharmaceutical's revenue composition shows that sales of pharmaceuticals and medical devices account for 98.84%, mobile healthcare for 0.86%, and leasing for 0.3% [2]

瑞康医药8月5日公告，公司于2024年11月7日召开第五届董事会第十次会议，审议通过了《关于回购公 司股份方案的议案》，同意公司使用银行专项贷款资金及自有资金以集中竞价交易方式回购公司部分已 发行的普通股（Ａ股），本次回购股份将用于实施员工持股计划，回购股份的资金总额不低于1亿元 （含），不超过2亿元（含），回购股份的价格不超过4.5元／股（含），具体回购股份的数量以回购期 限届满或回购完毕时实际回购的股份数量为准，实施期限为董事会审议通过回购股份方案之日起12个月 内。截至2025年7月31日，公司累计回购2044.65万股，占公司总股本的1.36％，回购价格区间为2.75元 ／股至3.08元／股，累计使用资金6039.63万元（不含交易费用）。 ...

Group 1 - The company, Ruikang Pharmaceutical, stated that as of July 10, 2025, the total number of shareholders is 73,669 [2]

Group 1 - The resignation of Han Chunlin, Vice President of Ruikang Pharmaceutical, is due to personal reasons and will not affect the board's operations or normal business activities [2][4] - Han Chunlin, born in 1993, has been with Ruikang Pharmaceutical since 2013, holding various positions and becoming Vice President in 2023 [3] - His departure adds uncertainty to the company, which is already facing operational pressures, with revenue declining from 27.2 billion in 2020 to 7.97 billion in 2024 [4] Group 2 - Han Chunlin's salary for 2024 was 904,400 yuan, significantly higher than the average of 467,300 yuan for other senior executives [3] - The company has been under pressure, with stock prices consistently below net asset value and previous attempts by the controlling shareholder to transfer shares failing [4] - Ruikang Pharmaceutical, established in 2004, is a leading player in the domestic pharmaceutical distribution sector, involved in drug distribution, medical devices, and digital healthcare [4]

Core Viewpoint - The frequent personnel changes at Ruikang Pharmaceutical are indicative of the company's declining performance, with significant revenue drops and market share losses over recent years [2][5]. Group 1: Company Performance - Ruikang Pharmaceutical's revenue has plummeted from a peak of 35.3 billion yuan in 2019 to 7.966 billion yuan in 2024, representing a decrease of approximately 77% [5]. - The company has fallen from being among the top 10 in the industry to outside the top 20, highlighting a significant decline in its market position [2]. - In 2023, Ruikang ranked 26th among pharmaceutical distribution companies, with major competitors like China National Pharmaceutical, Shanghai Pharmaceutical, and others significantly outperforming it [5]. Group 2: Business Strategy - Following a period of nationwide expansion, Ruikang has initiated a strategy of business contraction, focusing on core markets such as Shandong and Beijing [4]. - The company has been closing and transferring numerous subsidiaries, with 53 and 29 subsidiaries being closed or transferred in 2023 and 2024, respectively [4]. Group 3: Personnel Changes - The resignation of Vice President Han Chunlin and the detention of Secretary Li Zhe by local authorities have raised concerns about the company's governance and operational stability [2][5]. - The company claims that Han's departure was due to personal reasons and will not impact its operational development [2]. Group 4: Related Transactions - Ruikang's planned acquisition of a 76.01% stake in Zhejiang Hengjiu Medical Equipment for 151 million yuan has drawn scrutiny due to the target company's poor financial performance, with no revenue reported for three consecutive years [6][8]. - The acquisition is part of Ruikang's strategy to expand into the medical device sector, despite Zhejiang Hengjiu's ongoing losses and lack of revenue [9].

证券代码：002589 证券简称：瑞康医药 公告编号：2025-038 瑞康医药集团股份有限公司 关于公司董事、副总裁辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）董事会收到公司董事、副 总裁韩春林先生提交的书面辞职报告。韩春林先生因个人原因决定申请辞去公司 董事、副总裁职务以及公司及子公司的所有其他职务，辞职后将不再担任公司及 控股子公司任何职务。 根据《公司法》《公司章程》相关规定，韩春林先生的辞职不会导致公司董 事人数低于法定人数，不会影响董事会及董事会专门委员会正常运作和公司正常 生产经营。韩春林先生的辞职报告自送达公司董事会之日起生效。公司董事会将 根据《公司章程》等相关规定尽快进行董事补选工作。 公司董事会对韩春林先生在任职期间为公司发展所做出的贡献表示衷心感 谢。 特此公告。 瑞康医药集团股份有限公司 董 事 会 2025 年 7 月 14 日 1 截至本公告披露日，韩春林先生未持有公司股票，不存在未履行的承诺事项。 ...